News

Camlin Fine Sciences Ltd share price declined by 1.66% to Rs 124.35 after the company`s net profit witnessed a sharp fall of 138.97% to Rs 33.62 crore, while revenue from operations increased sharply by 22.38% to Rs 519.88 crore in Q2FY26 over Q1FY26. The market capitalization of Specialty Chemicals industry group stocks on BSE stood at Rs 5.09 lakh crore, rallying 15.27%. It has marginally improved by 1.74% over last one week and moving up by 12.24% in last one month while the market capitalization of Camlin Fine Sciences Ltd has eased by 4.75% and 4.63% in the same period respectively. Profit before tax (PBT) of Camlin Fine Sciences Ltd stood at Rs 34.09 crore in Q2 FY26, surging by 218.30% year-on-year, and plunging by 142.59% quarter-on-quarter. EBITDA came in at Rs 8 crore, tanking 41.87% YoY and nosediving by 391.91% sequentially. Total expenses surged 24.81% to Rs 529.76 crore in Q2FY26 over Q2FY25. During the quarter, cost of materials consumed stood at Rs 312.35 crore, soaring by 158.72% YoY, while employee benefits expense was at Rs 73.43 crore, rising by 11.38% YoY. For the TTM ended FY26, revenue from operations tick up 5.81% to Rs 1723.31 crore, while net profit tumbled by 148.44% to Rs 31.53 crore, compared to previous TTM. EBITDA soared by 20985% to Rs 78.09 crore, and PBT plunged by 149.54% to Rs 31.99 crore compared to previous TTM. The company`s consolidated net cash flow from operating activities stood at Rs 82.07 crore in FY26, as against Rs 23.0 crore in FY25. Camlin Fine Sciences Ltd crashed 44.31% in last one year, underperforming the benchmark BSE Sensex which has eased by 2.56% during the same period.

Camlin Fine Sciences will hold a meeting of the Board of Directors of the Company on 11 August 2026.

Camlin Fine Sciences announced that the 33th Annual General Meeting(AGM) of the company will be held on 11 August 2026.

Net profit of Camlin Fine Sciences reported to Rs 88.20 crore in the quarter ended March 2026 as against net loss of Rs 0.72 crore during the previous quarter ended March 2025. Sales declined 1.57% to Rs 424.81 crore in the quarter ended March 2026 as against Rs 431.58 crore during the previous quarter ended March 2025.For the full year,net profit reported to Rs 27.63 crore in the year ended March 2026 as against net loss of Rs 139.05 crore during the previous year ended March 2025. Sales rose 5.81% to Rs 1723.31 crore in the year ended March 2026 as against Rs 1628.69 crore during the previous year ended March 2025. ParticularsQuarter EndedYear EndedMar. 2026Mar. 2025% Var.Mar. 2026Mar. 2025% Var. Sales424.81431.58 -2 1723.311628.69 6 OPM %4.9914.38 -6.2013.26 - PBDT23.5160.10 -61 64.40135.35 -52 PBT2.6942.95 -94 -6.5274.39 PL NP88.20-0.72 LP 27.63-139.05 LP Powered by Capital Market - Live News

The board of Camlin Fine Sciences at its meeting held on 26 May 2026 has approved the appointment of Pankaj Pandey as Chief Financial Officer (CFO) and Key Managerial Personnel of the Company, effective 18 August 2026. Further, the board approved the re-designation of Santosh Parab, currently Chief Financial Officer, as President � Strategy and Global CFO, effective 18 August 2026.